Joincare Pharmaceutical (SHA:600380) extended its second-phase business partner stock ownership plan by 12 months to June 7, 2027.
The plan holds 6.3 million shares, or 0.33% of the pharmaceutical company's total share capital, according to a Tuesday filing with the Shanghai bourse.
Shares of Joincare Pharmaceutical were down 1% in recent trade.
Petrobras, operator of the BM-SEAL-11 consortium, of which Bharat Petroleum (NSE:BPCL, BOM:500547) is a part, has signed a contract for the construction of a floating production storage and offloading (FPSO) unit in Brazil, according to a Tuesday filing to the Indian stock exchanges.The FPSO will be built by SBM Offshore for the SEAP-I project in Brazil, which includes the development of oil and gas discovered in BM-SEAL-11 and BM-SEAL-10 concessions. The FPSO will have an installed capacity to process 120,000 barrels of oil/condensate per day and 10 million m³ of gas per day.Bharat Petroleum, through its subsidiaries, holds a 65.4% stake in IBV Brasil Petroleo, which in turn, holds 40% participating interest in the BM Seal 11 concession. IBV's total investment in the project is estimated at around $2.8 billion, subject to Government of India approvals.Under the contract, SBM Offshore will design, build, and operate the FPSO for an initial period of six and a half years, through a separate operation and maintenance contract.
Wesfarmers (ASX:WES) is well-positioned to take share in the current market backdrop, further supported by scale and digital, Jarden said in a note on Monday.It also expects positive earnings-per-share consensus revisions, underpinned by updated near-term lithium price forecasts.Wesfarmers is executing well and has a clear plan within the existing corporate envelope. In the medium term, there is a material opportunity for it to become the leading customer-facing business in Australia across health, consumables, goods, and energy, although this will require time and money, per the note.The investment firm retained its neutral rating on Wesfarmers and raised the price target to AU$75.30 per share from AU$74.50 per share.
Diatreme Resources (ASX:DRX) secured a further 12-month extension of its existing AU$1 million debt facility, with the maturity date extended to May 30, 2027, from May 30, according to a Tuesday Australian bourse filing.The facility remains unsecured and continues to carry an interest rate of 7.5% per annum, payable quarterly in arrears.The facility originated from a convertible note arrangement that was fully drawn by May 2, 2017. The debt component of the arrangement has been subject to various extensions and was reduced by AU$500,000 in 2024, leaving the current principal balance of AU$1 million.Its shares fell 6% in recent trading on Tuesday, reaching their lowest point in over five years.